Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/9/2025

SGLT2 Inhibitors for CKD Patients Without Diabetes

Evidence Supporting SGLT2 Inhibitors in Non-Diabetic CKD

  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines provide a strong recommendation (1A) for SGLT2 inhibitors in adults with CKD having eGFR ≥20 mL/min/1.73 m² with urine albumin-to-creatinine ratio (ACR) ≥200 mg/g, or heart failure, irrespective of albuminuria 1, 2
  • For adults with eGFR 20-45 mL/min/1.73 m² with urine ACR <200 mg/g, SGLT2 inhibitors are suggested with a 2B recommendation 1, 2
  • SGLT2 inhibitors are now recommended for CKD patients regardless of diabetes status, with strong evidence supporting their use in non-diabetic CKD patients 3, 4

Comparing Available SGLT2 Inhibitors for Non-Diabetic CKD

  • Can be initiated with eGFR >30 mL/min/1.73 m² according to FDA labeling, though clinical trials included participants with lower eGFR 5

Practical Considerations for SGLT2 Inhibitor Use in CKD

  • Initiate SGLT2 inhibitors when eGFR ≥20 mL/min/1.73 m² 4, 1
  • Once initiated, it is reasonable to continue SGLT2 inhibitors even if eGFR falls below 20 mL/min/1.73 m², unless not tolerated or kidney replacement therapy is initiated 1, 2
  • Withhold SGLT2 inhibitors during times of prolonged fasting, surgery, or critical medical illness due to increased risk of ketosis 1, 2
  • Monitor for potential adverse effects including genital mycotic infections, urinary tract infections, and volume depletion 4

Empagliflozin for Chronic Kidney Disease Without Diabetes

Mechanisms of Kidney Protection

  • The renoprotective effects of empagliflozin occur through mechanisms independent of glycemic control, including restoration of tubuloglomerular feedback, reduction in intraglomerular pressure, decreased renal tubular glucose reabsorption, reduction in systemic blood pressure, decreased albuminuria, reduction in oxidative stress, and decreased NLRP3 inflammasome activity, as reported in Kidney International 6
  • Empagliflozin decreases renal tubular glucose reabsorption, reduces systemic blood pressure, and decreases albuminuria, according to Diabetes Care 7
  • Empagliflozin reduces oxidative stress and decreases NLRP3 inflammasome activity, as published in Diabetes Care 8

Comparison with Other CKD Treatments

  • Empagliflozin has direct documented kidney benefit, unlike metformin, and provides cardiovascular protection in addition to kidney protection, with low risk of hypoglycemia, as noted in Diabetes Care 9